The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

CD30-directed Antibody-Tripeptide MMAE Conjugate

Geo Regions

CD30-directed Antibody-Tripeptide MMAE Conjugate

PF-08046045, SGN-35T is an investigational compound. Its safety and efficacy have not been established

Overview + Rationale

  • PF-08046045; SGN-35T is a CD30-directed ADC with the same mAb backbone and cytotoxic monomethyl auristatin E (MMAE) payload as BV and utilizes the novel cleavable tripeptide linker. 
  • CD30 is expressed in many B- and T-cell lymphomas while having limited expression in normal tissue2

Mechanism of Action

Stage of Development

small icon representing hematologic cancer
Lymphomas
Phase 1

REFERENCES: 1. Hamblett K. EORTC 2023: Poster C132; Wahl AF. Cancer Res. 2002: 3736-4; 2 Heiser R. MCT. 2023 10.1158/1535-7163.MCT-23-0118; 3. NCT06120504. https://clinicaltrials.gov/ct2/show/NCT06120504 Accessed February 25, 2024